Get the Stockscreener App
43.72
4.74%
1.98
Pre-market:
43.95
0.23
+0.53%
Quidelortho Corporation stock is traded at $43.72, with a volume of 850.24K.
It is up +4.74% in the last 24 hours and down -2.50% over the past month.
QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if the revenue from North America.
See More
Previous Close:
$41.74
Open:
$42.14
24h Volume:
850.24K
Relative Volume:
0.95
Market Cap:
$2.94B
Revenue:
$2.82B
Net Income/Loss:
$-1.87B
P/E Ratio:
-1.567
EPS:
-27.9
Net Cash Flow:
$-96.80M
1W Performance:
+6.37%
1M Performance:
-2.50%
6M Performance:
+26.03%
1Y Performance:
-38.72%
1-Day Range:
$42.14
$43.75
1-Week Range:
$39.18
$43.75
52-Week Range:
$29.73
$73.45
Quidelortho Corporation Stock (QDEL) Company Profile
Name
Quidelortho Corporation
Sector
Industry
Phone
(858) 552-1100
Address
9975 SUMMERS RIDGE ROAD, SAN DIEGO, CA
Compare QDEL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QDEL
Quidelortho Corporation
|
43.72 | 2.94B | 2.82B | -1.87B | -96.80M | -27.90 |
|
ABT
Abbott Laboratories
|
116.79 | 201.01B | 41.22B | 5.77B | 6.49B | 3.29 |
|
SYK
Stryker Corp
|
395.85 | 150.90B | 21.97B | 3.59B | 3.21B | 9.33 |
|
BSX
Boston Scientific Corp
|
100.91 | 148.72B | 15.91B | 1.79B | 1.89B | 1.21 |
|
MDT
Medtronic Plc
|
88.38 | 113.33B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
69.97 | 41.27B | 6.60B | 4.16B | 490.10M | 6.93 |
Quidelortho Corporation Stock (QDEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-24 | Upgrade | Citigroup | Neutral → Buy |
| Dec-10-24 | Initiated | Jefferies | Hold |
| Sep-19-24 | Resumed | UBS | Neutral |
| Sep-05-24 | Upgrade | Craig Hallum | Hold → Buy |
| Mar-04-24 | Downgrade | UBS | Neutral → Sell |
| Feb-14-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-11-23 | Downgrade | Citigroup | Buy → Neutral |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-14-22 | Upgrade | UBS | Sell → Neutral |
| Sep-19-22 | Initiated | Citigroup | Neutral |
| Jul-20-22 | Initiated | UBS | Sell |
| Jun-17-22 | Resumed | JP Morgan | Neutral |
| Feb-22-22 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jan-22-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-12-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-26-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-23-18 | Resumed | Raymond James | Strong Buy |
| Mar-08-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jan-22-18 | Reiterated | Barclays | Overweight |
| Jan-04-18 | Upgrade | CL King | Neutral → Buy |
| Sep-19-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-18-17 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jul-18-17 | Upgrade | William Blair | Mkt Perform → Outperform |
| Apr-25-17 | Reiterated | Canaccord Genuity | Hold |
| Feb-17-17 | Initiated | CL King | Neutral |
| Dec-16-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jun-13-16 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Feb-18-16 | Reiterated | Barclays | Overweight |
| Feb-09-16 | Downgrade | Canaccord Genuity | Buy → Hold |
| Jan-08-16 | Reiterated | Canaccord Genuity | Buy |
| Dec-14-15 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Sep-02-15 | Initiated | Barclays | Overweight |
| Jul-31-13 | Reiterated | Canaccord Genuity | Buy |
| Mar-03-11 | Downgrade | Wedbush | Outperform → Neutral |
View All
Quidelortho Corporation Stock (QDEL) Latest News
QuidelOrtho Stock Down Despite Solid Preliminary Q4 Revenues - MSN
QuidelOrtho (NASDAQ:QDEL shareholders incur further losses as stock declines 6.4% this week, taking three-year losses to 59% - Simply Wall St
QuidelOrtho may be takeover, activist target with CEO exit, share slumpanalyst - MSN
Oak Thistle LLC Acquires New Stake in QuidelOrtho Co. (NASDAQ:QDEL) - MarketBeat
QuidelOrtho lets go off CEO Douglas Bryant - MSN
QuidelOrtho Breaks Below 200-Day Moving AverageNotable for QDEL - Nasdaq
QuidelOrtho (NASDAQ:QDEL) Stock Price Down 3.2%Here's Why - MarketBeat
Why QuidelOrtho Shares Are Struggling Despite Optimism - TipRanks
Moody National Bank Trust Division Grows Position in QuidelOrtho Co. (NASDAQ:QDEL) - MarketBeat
QuidelOrtho reports Q4 revenue in line with guidance By Investing.com - Investing.com Australia
QuidelOrtho Corp (QDEL) Trading Down 4.21% on Jan 13 - GuruFocus.com
QuidelOrtho sees Q4 revenue $702M -$707M, consensus $698.04M - TipRanks
QuidelOrtho announces preliminary Q4 2024 revenue in range of $702 million to $707 million - MSN
QuidelOrtho reports Q4 revenue in line with guidance - Investing.com
QuidelOrtho Announces Preliminary Unaudited Revenue for Fourth Quarter 2024 - The Bakersfield Californian
Barclays PLC Sells 41,945 Shares of QuidelOrtho Co. (NASDAQ:QDEL) - MarketBeat
Stocks Showing Improved Relative Strength: QuidelOrtho - Inkl
Quidel completes Ortho deal, emerges as QuidelOrtho - LabPulse
Kuehn Law Encourages Investors of QuidelOrtho Corporation to Contact Law Firm - PR Newswire
JPMorgan Chase & Co. Has $56.25 Million Stock Holdings in QuidelOrtho Co. (NASDAQ:QDEL) - MarketBeat
Immunoassay Market Strategies, Trends. Forecasts Report 2025: The Drive Towards Newer, More Efficient Diagnostic Instruments - GlobeNewswire Inc.
QuidelOrtho to Present at the 43rd Annual J.P. Morgan Healthcare Conference - BioSpace
QuidelOrtho Co. (NASDAQ:QDEL) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
QuidelOrtho Co. (NASDAQ:QDEL) Stock Position Increased by Principal Financial Group Inc. - MarketBeat
QuidelOrtho files to sell 8.26M shares of common stocks by selling shareholders - MSN
QuidelOrtho Co. (NASDAQ:QDEL) Shares Sold by Barclays PLC - MarketBeat
Geode Capital Management LLC Buys 16,059 Shares of QuidelOrtho Co. (NASDAQ:QDEL) - MarketBeat
Does QuidelOrtho Corporation (QDEL) Have Healthy Long-Term Growth Prospects? - MSN
Insider Buying: QuidelOrtho President Bought US$250k Of Shares - Yahoo Finance
QuidelOrtho's SWOT analysis: stock upgrade amid cost cuts, product launch By Investing.com - Investing.com Australia
State Street Corp Boosts Holdings in QuidelOrtho Co. (NASDAQ:QDEL) - MarketBeat
QuidelOrtho's SWOT analysis: stock upgrade amid cost cuts, product launch - Investing.com
Quantinno Capital Management LP Trims Stock Position in QuidelOrtho Co. (NASDAQ:QDEL) - MarketBeat
QuidelOrtho Co. (NASDAQ:QDEL) Shares Sold by The Manufacturers Life Insurance Company - MarketBeat
Brian J. Blaser Buys 6,033 Shares of QuidelOrtho Co. (NASDAQ:QDEL) Stock - MarketBeat
QuidelOrtho Announces Appointment of Two Independent Directors to its Board - Milton Daily Standard
Citigroup Upgrades QuidelOrtho (QDEL) - MSN
Citi upgrades Quidel stock to Buy on FY25 growth prospects and margin improvement efforts - Investing.com
QuidelOrtho (NASDAQ:QDEL) Upgraded at Citigroup - MarketBeat
QuidelOrtho expands board with healthcare veterans By Investing.com - Investing.com Canada
QuidelOrtho upgraded to Buy from Neutral at Citi - TipRanks
MetLife Investment Management LLC Sells 25,230 Shares of QuidelOrtho Co. (NASDAQ:QDEL) - MarketBeat
Jefferies Initiates Coverage of QuidelOrtho (QDEL) with Hold Recommendation - MSN
QuidelOrtho's SWOT analysis: stock outlook amid strategic shifts, market challenges - Investing.com Nigeria
QuidelOrtho (NASDAQ:QDEL) Coverage Initiated at Jefferies Financial Group - MarketBeat
QuidelOrtho expands board with healthcare veterans - Investing.com India
QuidelOrtho Strengthens Board with Experienced Healthcare CEOs - TipRanks
Quidelortho Corporation Stock (QDEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):